Details of the Drug
General Information of Drug (ID: DMCJ1B2)
| Drug Name |
MT-500
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
199864-87-4; RS-127445; 4-(4-fluoronaphthalen-1-yl)-6-isopropylpyrimidin-2-amine; RS 127445; UNII-0JAU3P8OBM; MT 500; 0JAU3P8OBM; CHEMBL473186; C17H16FN3; RS-127445 HCl; 2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine; RS127445; 2-Pyrimidinamine, 4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-; RS-127,445; 4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine; AC1L52MZ; GTPL188; RS 127445 hydrochloride/; SCHEMBL375979; MolPort-021-804-999; ZZZQXCUPAJFVBN-UHFFFAOYSA-N; HMS3651H11; BCPP000085; BCP02714; ZINC3961115
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 281.33 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Migraine | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 8A80 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


